Lv51
1040 积分 2024-01-30 加入
Covalent Inhibitors of Interleukin‑2 Inducible T Cell Kinase (Itk) with Nanomolar Potency in a Whole-Blood Assay
10小时前
已关闭
Updated patent review for hematopoietic progenitor kinase (HPK1) inhibitors and degraders (2021-present)
1个月前
已完结
An updated review of small-molecule HPK1 kinase inhibitors (2016-present)
1个月前
已完结
Current strategies for targeting HPK1 in cancer and the barriers to preclinical progress
1个月前
已完结
Targeting HPK1 for cancer immunotherapy: An update on recent medicinal chemistry advances
1个月前
已完结
Discovery of HDM2004, a potent, selective and orally bioavailable HPK1 inhibitor for tumor immunotherapy
1个月前
已完结
Current and future status of JAK inhibitors
2个月前
已完结
Advances in the design and discovery of next-generation janus kinase-2 (JAK2) inhibitors for the treatment of myeloproliferative neoplasms
2个月前
已完结
Design, synthesis and structure–activity relationship of indolylindazoles as potent and selective covalent inhibitors of interleukin-2 inducible T-cell kinase (ITK)
3个月前
已完结
Isoxazole-pyrimidine derivatives as TACC3 inhibitors: A novel modality to targeted cancer therapy
4个月前
已完结
皖公网安备34019202002308
